Pub Date : 2012-06-01DOI: 10.1097/01.PSYPHR.0000415488.63708.04
A. Barnhorst, Glen Xiong
{"title":"Topiramate: Off-Label Use in Psychiatric Disorders","authors":"A. Barnhorst, Glen Xiong","doi":"10.1097/01.PSYPHR.0000415488.63708.04","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000415488.63708.04","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000415488.63708.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-05-01DOI: 10.1097/01.PSYPHR.0000413717.29353.5f
W. Gilmer, Jennifer N. Zarnicki
1 provided an overview of available research reports on transcranial magnetic stimulation (TMS) for bipolar illness. In that edition, we also introduced the rationale for pursuing TMS for treatment-resistant bipolar depression. Notably, only two pharmacologic treatments are currently FDA-approved for acute treatment of bipolar depression, despite the disproportionate amount of time spent in depression by most patients with bipolar illness. This is in marked contrast to the sizeable number of pharmacologic agents that have come on the market in the past two decades for treatment of mania, and similarly in contrast to the large number of agents approved for unipolar depression. It also appears that traditional antidepressants may have much more limited value than previously assumed for many patients suffering from bipolar disorders. Thus, clinicians may to turn to TMS as an alternative for patients with treatment-resistant bipolar depression when antidepressants have not been adequately effective or tolerated. This companion article to last month’s edition offers realworld, clinical observations regarding the practical use of TMS in treating bipolar depression. Although research and clinical experience to-date suggest the application of TMS for bipolar depression is promising, its use also presents a number of clinical challenges unique to bipolar illness (Table 1) and raises several questions to be addressed through future investigation (Table 2). Thus far, our clinical experience echoes the promise seen in earlier studies. We have treated 11 patients with bipolar illness (bipolar II, 9; bipolar not otherwise specified After participating in this CME activity, the psychiatrist should be better able to: • Determine which patients with treatment-resistant bipolar depression may be appropriate candidates for transcranial magnetic stimulation (TMS). • Assess clinical challenges in the use of TMS for bipolar depression. • Appraise the potential role of TMS in the integrated treatment of bipolar disorder.
{"title":"Transcranial Magnetic Stimulation for Bipolar Depression: A Clinical Perspective","authors":"W. Gilmer, Jennifer N. Zarnicki","doi":"10.1097/01.PSYPHR.0000413717.29353.5f","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000413717.29353.5f","url":null,"abstract":"1 provided an overview of available research reports on transcranial magnetic stimulation (TMS) for bipolar illness. In that edition, we also introduced the rationale for pursuing TMS for treatment-resistant bipolar depression. Notably, only two pharmacologic treatments are currently FDA-approved for acute treatment of bipolar depression, despite the disproportionate amount of time spent in depression by most patients with bipolar illness. This is in marked contrast to the sizeable number of pharmacologic agents that have come on the market in the past two decades for treatment of mania, and similarly in contrast to the large number of agents approved for unipolar depression. It also appears that traditional antidepressants may have much more limited value than previously assumed for many patients suffering from bipolar disorders. Thus, clinicians may to turn to TMS as an alternative for patients with treatment-resistant bipolar depression when antidepressants have not been adequately effective or tolerated. This companion article to last month’s edition offers realworld, clinical observations regarding the practical use of TMS in treating bipolar depression. Although research and clinical experience to-date suggest the application of TMS for bipolar depression is promising, its use also presents a number of clinical challenges unique to bipolar illness (Table 1) and raises several questions to be addressed through future investigation (Table 2). Thus far, our clinical experience echoes the promise seen in earlier studies. We have treated 11 patients with bipolar illness (bipolar II, 9; bipolar not otherwise specified After participating in this CME activity, the psychiatrist should be better able to: • Determine which patients with treatment-resistant bipolar depression may be appropriate candidates for transcranial magnetic stimulation (TMS). • Assess clinical challenges in the use of TMS for bipolar depression. • Appraise the potential role of TMS in the integrated treatment of bipolar disorder.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000413717.29353.5f","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-04-01DOI: 10.1097/01.PSYPHR.0000413086.80585.CE
W. Gilmer, Jennifer N. Zarnicki
{"title":"Review of Transcranial Magnetic Stimulation for Bipolar Disorder","authors":"W. Gilmer, Jennifer N. Zarnicki","doi":"10.1097/01.PSYPHR.0000413086.80585.CE","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000413086.80585.CE","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000413086.80585.CE","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-03-01DOI: 10.1097/01.PSYPHR.0000411896.67142.2d
M. Moran, Natalie C. Dattilo
{"title":"Psychiatric Issues in Patients With Cancer","authors":"M. Moran, Natalie C. Dattilo","doi":"10.1097/01.PSYPHR.0000411896.67142.2d","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000411896.67142.2d","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000411896.67142.2d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-02-01DOI: 10.1097/01.PSYPHR.0000410254.32502.c5
L. Hulvershorn, David D. Fosselman, D. Dickstein, P. Janicak
{"title":"Psychopharmacology of Nonepisodic Irritability, Aggression, and Mood Swings in Children And Adolescents: Part II Antipsychotics, Antimanic Agents, and Alpha Agonists","authors":"L. Hulvershorn, David D. Fosselman, D. Dickstein, P. Janicak","doi":"10.1097/01.PSYPHR.0000410254.32502.c5","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000410254.32502.c5","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000410254.32502.c5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-01-01DOI: 10.1097/01.PSYPHR.0000410252.86760.05
L. Hulvershorn, David D. Fosselman, D. Dickstein, P. Janicak
{"title":"Psychopharmacology of Nonepisodic Irritability, Aggression, and Mood Swings in Children And Adolescents: Part I Stimulants and Antidepressants","authors":"L. Hulvershorn, David D. Fosselman, D. Dickstein, P. Janicak","doi":"10.1097/01.PSYPHR.0000410252.86760.05","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000410252.86760.05","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000410252.86760.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-01DOI: 10.1097/01.PSYPHR.0000410133.47951.30
A. Anand, S. Mathew, P. Janicak
{"title":"Ketamine Treatment for Major Depression","authors":"A. Anand, S. Mathew, P. Janicak","doi":"10.1097/01.PSYPHR.0000410133.47951.30","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000410133.47951.30","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000410133.47951.30","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-11-01DOI: 10.1097/01.PSYPHR.0000407109.91433.4c
Kelly Blankenship, P. Janicak
trum disorders (ASDs) over the past 2 decades. The most recent data suggest that 1 in 110 children and 1 in 70 male children will be diagnosed with an ASD. As the prevalence of ASDs has increased, so has the number of pharmacologic studies performed to address the associated interfering symptoms (ie, inattention/ hyperactivity, irritability/aggression, interfering repetitive and stereotypic behavior, and social deficits). This article discusses pharmacologic studies, which have attempted to address these symptoms and improve this population’s ability to function. HYPERACTIVITY AND INATTENTION Hyperactivity and inattention are frequently exhibited by individuals with ASDs. These are usually children who have difficulty staying focused without redirection and encounter problems staying seated in the same place for long periods of time. Even though these symptoms are common in individuals with ASDs, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), excludes the diagnosis of attention-deficit/hyperactivity disorder (ADHD) in this population. There have been multiple studies with conflicting conclusions regarding the use of methylphenidate (MPH) in ASDs. Some studies suggest improvement in inattention and hyperactivity with MPH, whereas others report limited benefit and numerous adverse events. In one double-blind, placebo-controlled, crossover study, 10 children (ages 7–11 years) with ASDs were prescribed MPH (10 or 20 mg BID) or placebo. A small, statistically significant improvement in the MPH versus placebo group was captured on the Aberrant Behavior Checklist (ABC)-Hyperactivity Subscale (P 0.02) and Conners After participating in this CME activity, the psychiatrist should be better able to: • Choose the most effective medication for treatment of hyperactivity and inattention associated with autism spectrum disorders (ASDs). • Select firstand second-generation antipsychotics to treat irritability/aggression in patients with ASDs. • Assess the results of pharmacologic treatment for repetitive/stereotypic behaviors in patients with ASDs. • Evaluate the results of studies of memantine in patients with ASD who also have socialization issues.
{"title":"Pharmacotherapy of Autism Spectrum Disorders","authors":"Kelly Blankenship, P. Janicak","doi":"10.1097/01.PSYPHR.0000407109.91433.4c","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000407109.91433.4c","url":null,"abstract":"trum disorders (ASDs) over the past 2 decades. The most recent data suggest that 1 in 110 children and 1 in 70 male children will be diagnosed with an ASD. As the prevalence of ASDs has increased, so has the number of pharmacologic studies performed to address the associated interfering symptoms (ie, inattention/ hyperactivity, irritability/aggression, interfering repetitive and stereotypic behavior, and social deficits). This article discusses pharmacologic studies, which have attempted to address these symptoms and improve this population’s ability to function. HYPERACTIVITY AND INATTENTION Hyperactivity and inattention are frequently exhibited by individuals with ASDs. These are usually children who have difficulty staying focused without redirection and encounter problems staying seated in the same place for long periods of time. Even though these symptoms are common in individuals with ASDs, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), excludes the diagnosis of attention-deficit/hyperactivity disorder (ADHD) in this population. There have been multiple studies with conflicting conclusions regarding the use of methylphenidate (MPH) in ASDs. Some studies suggest improvement in inattention and hyperactivity with MPH, whereas others report limited benefit and numerous adverse events. In one double-blind, placebo-controlled, crossover study, 10 children (ages 7–11 years) with ASDs were prescribed MPH (10 or 20 mg BID) or placebo. A small, statistically significant improvement in the MPH versus placebo group was captured on the Aberrant Behavior Checklist (ABC)-Hyperactivity Subscale (P 0.02) and Conners After participating in this CME activity, the psychiatrist should be better able to: • Choose the most effective medication for treatment of hyperactivity and inattention associated with autism spectrum disorders (ASDs). • Select firstand second-generation antipsychotics to treat irritability/aggression in patients with ASDs. • Assess the results of pharmacologic treatment for repetitive/stereotypic behaviors in patients with ASDs. • Evaluate the results of studies of memantine in patients with ASD who also have socialization issues.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000407109.91433.4c","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-10-01DOI: 10.1097/01.PSYPHR.0000406482.50261.8e
E. Scott, K. Perri, P. Janicak
{"title":"Psychopharmacologic Treatment of Chronic Pain in Children and Adolescents","authors":"E. Scott, K. Perri, P. Janicak","doi":"10.1097/01.PSYPHR.0000406482.50261.8e","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000406482.50261.8e","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000406482.50261.8e","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-09-01DOI: 10.1097/01.PSYPHR.0000400271.39708.36
B. Vitiello
{"title":"Treating Depression in Adolescents","authors":"B. Vitiello","doi":"10.1097/01.PSYPHR.0000400271.39708.36","DOIUrl":"https://doi.org/10.1097/01.PSYPHR.0000400271.39708.36","url":null,"abstract":"","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.PSYPHR.0000400271.39708.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61610286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：